GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » EV-to-Revenue

Appili Therapeutics (Appili Therapeutics) EV-to-Revenue : 9.50 (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Appili Therapeutics's enterprise value is $8.07 Mil. Appili Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.85 Mil. Therefore, Appili Therapeutics's EV-to-Revenue for today is 9.50.

The historical rank and industry rank for Appili Therapeutics's EV-to-Revenue or its related term are showing as below:

APLIF' s EV-to-Revenue Range Over the Past 10 Years
Min: -79.08   Med: 30.07   Max: 376.02
Current: 10.06

During the past 6 years, the highest EV-to-Revenue of Appili Therapeutics was 376.02. The lowest was -79.08. And the median was 30.07.

APLIF's EV-to-Revenue is ranked worse than
54.48% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs APLIF: 10.06

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Appili Therapeutics's stock price is $0.0258. Appili Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, Appili Therapeutics's PS Ratio for today is 3.69.


Appili Therapeutics EV-to-Revenue Historical Data

The historical data trend for Appili Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics EV-to-Revenue Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial - 110.65 - 4.94 30.09

Appili Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 30.09 32.35 21.28 10.14

Competitive Comparison of Appili Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Appili Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Appili Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's EV-to-Revenue falls into.



Appili Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Appili Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8.069/0.849
=9.50

Appili Therapeutics's current Enterprise Value is $8.07 Mil.
Appili Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics  (OTCPK:APLIF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Appili Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0258/0.007
=3.69

Appili Therapeutics's share price for today is $0.0258.
Appili Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Appili Therapeutics (Appili Therapeutics) Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.